Inclisiran的研究进展

Research Progress of Inclisiran

血脂异常的治疗原则是通过降脂治疗来降低患者动脉粥样硬化性心血管疾病的风险。现目前各类指南及专家共识均建议对于符合超高危ASCVD的患者,将LDL-C的干预靶标降低至1.4 mmol/L并且基线降幅超过50%以上。抑制前蛋白转化酶枯草溶菌素9 (Proprotein convertase subtilisin/kexin type 9, PCSK9)是降低低密度脂蛋白胆固醇的新靶点。Inclisiran是一种小干扰RNA (siRNA)药物,可通过阻止肝细胞内PCSK9 mRNA的翻译,减少细胞内前蛋白转化酶枯草溶菌素9 (PCSK9)的产生,进而达到降脂作用,是最新获批的抑制PCSK9的药物。

The treatment principle of dyslipidemia is to reduce the risk of atherosclerotic cardiovascular dis-ease through lipid-lowering treatment. At present, various guidelines and expert consensus suggest that for patients with ultra-high risk ASCVD, the intervention target of LDL-C should be reduced to 1.4 mmol/l, and the baseline decrease should be more than 50%. Proprotein convertase subtil-isin/kexin type 9 (PCSK9) is a new target to reduce low density lipoprotein cholesterol (LDL-C). In-clisiran is a small interfering RNA (siRNA) drug, which can reduce the production of intracellular Proprotein convertase subtilisin/kexin type 9 (PCSK9) by preventing the translation of PCSK9 mRNA in hepatocytes, so as to achieve lipid-lowering effect. It is the latest approved drug to inhibit PCSK9.